Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma
Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma
复制标题
DOI：
10.1016/j.ygyno.2006.07.006
复制
发表时间：
2007-01-01
影响因子：
4.7
通讯作者：
Bae, Duk-Soo
中科院分区：
文献类型：
--
作者：
Choi, Chel Hun;Kim, Tae-Joong;Bae, Duk-Soo
目标。评价丝裂霉素C、长春新碱和顺铂联合新辅助化疗(NAC)治疗巨块型宫颈癌的疗效和毒副反应。10 mg/m(2)。46例IB2~IIB期宫颈癌患者用丝裂霉素-长春新碱1 mg/m(2)联合顺铂75 mg/m(2)静脉滴注，每3周一次。在三个NAC周期后，患者接受手术或放射治疗，这取决于他们是否适合根治性子宫切除术。这项研究的46名患者均适合NAC后的手术治疗。20例(44%)患者术后有危险因素，术后接受放射治疗。毒性非血液反应主要包括1-2级恶心和呕吐(87%)，最常见的血液毒性是贫血(60%)。临床缓解率为83%(38/46)，其中完全缓解率(CR)为24%(11/46)，病理完全缓解率为13%(6/46)。中位随访期28个月，3年无瘤生存率为74%，总生存率为80%。病理证实的淋巴结转移或宫旁受累以及肿瘤大小<4 cm与无瘤生存期缩短有关(P=0.040，P=0.000，P=0.025)。静脉注射MVC作为NAC似乎对IB2到IIB期宫颈癌患者有很好的耐受性和益处。(C)2006 Elsevier Inc.保留所有权利。
Objective. The efficacy and toxicity of neoadjuvant chemotherapy (NAC) with mitomycin-C, vincristine and cisplatin (MVC) were assessed in bulky cervical carcinoma patients. 10 mg/m(2),Methods. Forty-six patients with stage IB2 to IIB cervical cancer were treated with intravenous combination of mitomycin-C vincristine 1 mg/m(2) and cisplatin 75 mg/m(2) every 3 weeks. After three cycles of NAC, the patients either underwent surgery or radiation therapy, depending on their suitability for radical hysterectomy.Results. All 46 patients enrolled in this study were suitable for surgery after NAC. Twenty (44%) patients had risk factors after surgery and received postoperative radiation. Toxic nonhematologic reactions consisted primarily of grades 1-2 nausea and vomiting (87%) and the most common hematologic toxicity was anemia (60%). Clinical responses occurred in 83% (38/46) of patients, including 24% (11/46) with a complete response (CR) and 13% (6/46) with a pathologically determined complete response. For a median follow up period of 28 months, the 3-year disease-free and overall survival rates were 74% and 80%, respectively. Pathologically confirmed lymph node metastasis or parametrial involvement and an initial tumor size >= 4 cm were associated with shorter disease-free survival (P=0.040, P=0.000, P=0.025, respectively).Conclusion. Intravenous administration of MVC as a NAC seems to be well tolerated and beneficial in patients with stage IB2 to IIB cervical cancer. (c) 2006 Elsevier Inc. All rights reserved.